JP6122427B2 - ダルナビル複合製剤 - Google Patents

ダルナビル複合製剤 Download PDF

Info

Publication number
JP6122427B2
JP6122427B2 JP2014517822A JP2014517822A JP6122427B2 JP 6122427 B2 JP6122427 B2 JP 6122427B2 JP 2014517822 A JP2014517822 A JP 2014517822A JP 2014517822 A JP2014517822 A JP 2014517822A JP 6122427 B2 JP6122427 B2 JP 6122427B2
Authority
JP
Japan
Prior art keywords
darunavir
silicon dioxide
oral formulation
hypromellose
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014517822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520787A5 (enExample
JP2014520787A (ja
Inventor
アルフォンス シー． デラエト，アーバイン
アルフォンス シー． デラエト，アーバイン
エルナ エイチ． ヘインズ，フィリップ
エルナ エイチ． ヘインズ，フィリップ
マリア ヨゼフ ヤンス，ユージーン
マリア ヨゼフ ヤンス，ユージーン
エム． メルテンス，ロエル，ジョス
エム． メルテンス，ロエル，ジョス
デル アヴォート，ギールト ヴァン
デル アヴォート，ギールト ヴァン
Original Assignee
ヤンセン・サイエンシズ・アイルランド・ユーシー
ギリアード サイエンシーズ， インコーポレイテッド
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン・サイエンシズ・アイルランド・ユーシー, ギリアード サイエンシーズ， インコーポレイテッド, ギリアード サイエンシーズ， インコーポレイテッド filed Critical ヤンセン・サイエンシズ・アイルランド・ユーシー
Publication of JP2014520787A publication Critical patent/JP2014520787A/ja
Publication of JP2014520787A5 publication Critical patent/JP2014520787A5/ja
Application granted granted Critical
Publication of JP6122427B2 publication Critical patent/JP6122427B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014517822A 2011-07-07 2012-07-06 ダルナビル複合製剤 Active JP6122427B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173067 2011-07-07
EP11173067.7 2011-07-07
PCT/EP2012/063249 WO2013004818A1 (en) 2011-07-07 2012-07-06 Darunavir combination formulations

Publications (3)

Publication Number Publication Date
JP2014520787A JP2014520787A (ja) 2014-08-25
JP2014520787A5 JP2014520787A5 (enExample) 2015-08-13
JP6122427B2 true JP6122427B2 (ja) 2017-04-26

Family

ID=46551505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517822A Active JP6122427B2 (ja) 2011-07-07 2012-07-06 ダルナビル複合製剤

Country Status (24)

Country Link
US (3) US20140142070A1 (enExample)
EP (1) EP2729130B1 (enExample)
JP (1) JP6122427B2 (enExample)
KR (1) KR102058097B1 (enExample)
CN (1) CN103826616B (enExample)
AU (1) AU2012280198B2 (enExample)
BR (1) BR112014000290B1 (enExample)
CA (1) CA2838659C (enExample)
CY (1) CY1121999T1 (enExample)
DK (1) DK2729130T3 (enExample)
EA (1) EA026587B1 (enExample)
ES (1) ES2651212T3 (enExample)
HR (1) HRP20171889T1 (enExample)
HU (1) HUE035241T2 (enExample)
IL (1) IL229933A (enExample)
LT (1) LT2729130T (enExample)
MX (1) MX343689B (enExample)
NO (1) NO2729130T3 (enExample)
PL (1) PL2729130T3 (enExample)
PT (1) PT2729130T (enExample)
RS (1) RS56667B1 (enExample)
SI (1) SI2729130T1 (enExample)
SM (1) SMT201700574T1 (enExample)
WO (1) WO2013004818A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140142070A1 (en) 2011-07-07 2014-05-22 Janssen R&D Ireland Darunavir combination formulations
JP2015508822A (ja) * 2012-03-01 2015-03-23 ギリアード サイエンシーズ， インコーポレイテッド 噴霧乾燥製剤
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
SI3346995T1 (sl) 2015-11-09 2019-11-29 Gilead Sciences Inc Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
WO2018029566A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited A high drug loaded tablet composition for treating hiv
ES2952878T3 (es) * 2016-08-08 2023-11-06 Hetero Labs Ltd Una composición antirretroviral multiclase
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
EP3518935A1 (en) * 2016-09-27 2019-08-07 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
BR112020000842A2 (pt) 2017-07-20 2020-07-21 Janssen Sciences Ireland Unlimited Company composições e métodos para tratamento do hiv
WO2020064980A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of treating and preventing neuropsychiatric and/or neurocognitive complications in patients infected with hiv
WO2021180963A1 (en) 2020-03-13 2021-09-16 Janssen Sciences Ireland Unlimited Company A protease inhibitor regimen for treating subjects infected with hiv
CN119700779B (zh) * 2024-11-28 2025-11-04 安徽贝克生物制药有限公司 一种达芦那韦和考比司他复合片剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
DK0715618T3 (da) 1993-08-24 1999-08-23 Searle & Co Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
PT2336134T (pt) 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
JP4864320B2 (ja) 2002-05-16 2012-02-01 テイボテク・フアーマシユーチカルズ・リミテツド Ｈｉｖプロテアーゼ阻害剤の疑似多形相
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
JP5285603B2 (ja) 2006-05-30 2013-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ３受容体のモジュレーターとしての置換ピリジルアミド化合物
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
AR061838A1 (es) 2006-07-07 2008-09-24 Gilead Sciences Inc Moduladores de propiedades farmacocineticas de terapeuticos
US20080113021A1 (en) * 2006-10-25 2008-05-15 Robert Shen Ibuprofen composition
TWI533868B (zh) 2007-02-23 2016-05-21 吉李德科學股份有限公司 治療劑藥物動力學性質之調節劑
AU2008267237A1 (en) * 2007-06-25 2008-12-31 Tibotec Pharmaceuticals Combination formulations comprising darunavir and etravirine
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
MY158253A (en) 2007-11-20 2016-09-30 Janssen Pharmaceutica Nv Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
SG10201609006WA (en) * 2008-05-02 2016-12-29 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
US20100285122A1 (en) * 2009-02-06 2010-11-11 Gilead Sciences, Inc. Tablets for combination therapy
PL2477992T3 (pl) * 2009-09-17 2017-07-31 Mylan Laboratories Limited Proces przygotowania Darunawiru i jego amorficznych postaci
ES2699183T3 (es) 2010-05-10 2019-02-07 Hetero Research Foundation Composiciones de darunavir
DK2729128T3 (en) 2011-07-07 2016-11-21 Janssen Sciences Ireland Uc Darunavir-FORMULATIONS
US20140142070A1 (en) 2011-07-07 2014-05-22 Janssen R&D Ireland Darunavir combination formulations
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
US20170348334A1 (en) 2015-01-03 2017-12-07 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Also Published As

Publication number Publication date
BR112014000290B1 (pt) 2022-05-10
CA2838659C (en) 2020-02-18
EP2729130B1 (en) 2017-09-06
AU2012280198A8 (en) 2014-01-16
BR112014000290A2 (pt) 2017-02-07
US20140142070A1 (en) 2014-05-22
CY1121999T1 (el) 2020-07-31
DK2729130T3 (en) 2017-12-11
HUE035241T2 (en) 2018-05-02
MX343689B (es) 2016-11-16
HRP20171889T1 (hr) 2018-01-12
CN103826616B (zh) 2016-08-10
JP2014520787A (ja) 2014-08-25
MX2013015199A (es) 2014-09-01
US20200093840A1 (en) 2020-03-26
PL2729130T3 (pl) 2018-02-28
RS56667B1 (sr) 2018-03-30
AU2012280198B2 (en) 2016-12-22
US11654150B2 (en) 2023-05-23
LT2729130T (lt) 2018-01-10
KR102058097B1 (ko) 2019-12-20
AU2012280198A1 (en) 2014-01-09
PT2729130T (pt) 2017-12-13
US20230302024A1 (en) 2023-09-28
EA201490222A1 (ru) 2014-04-30
SMT201700574T1 (it) 2018-01-11
IL229933A (en) 2017-09-28
CA2838659A1 (en) 2013-01-10
WO2013004818A1 (en) 2013-01-10
CN103826616A (zh) 2014-05-28
SI2729130T1 (en) 2018-03-30
ES2651212T3 (es) 2018-01-25
EA026587B1 (ru) 2017-04-28
EP2729130A1 (en) 2014-05-14
KR20140068845A (ko) 2014-06-09
NO2729130T3 (enExample) 2018-02-03

Similar Documents

Publication Publication Date Title
JP6122427B2 (ja) ダルナビル複合製剤
JP6101260B2 (ja) ダルナビル製剤
CN104784133A (zh) 一种齐多夫定的片剂及其制备方法
HK1146708A (en) Combination formulations comprising darunavir and etravirine

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150624

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150915

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160923

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170331

R150 Certificate of patent or registration of utility model

Ref document number: 6122427

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250